Mostrar el registro sencillo del ítem

dc.contributor.advisorDuran Lengua, Marlene
dc.contributor.advisorMachado Alba, Jorge Enrique
dc.contributor.authorValladales Restrepo, Luis Fernando
dc.date.accessioned2023-01-22T16:24:02Z
dc.date.available2023-01-22T16:24:02Z
dc.date.issued2018
dc.identifier.urihttps://hdl.handle.net/11227/15917
dc.identifier.urihttp://dx.doi.org/10.57799/11227/1307
dc.description.abstractLas fracturas en el adulto mayor son una causa frecuente de morbilidad y mortalidad, en donde están implicados múltiples factores, entre ellos la cantidad de medicamentos, las prescripciones potencialmente inapropiadas, la carga anticolinérgica y sus reacciones adversas. El objetivo fue identificar y comparar la carga anticolinérgica empleando varios instrumentos en los pacientes con fracturas evaluando las prescripciones previas al evento, durante la atención hospitalaria y posteriores al egreso en 3 centros de referencia de Colombia. Materiales y métodos: Estudio analítico de concordancia, realizado en pacientes con diagnóstico de fracturas vertebrales y no vertebrales entre el 1 de enero y 30 de junio de 2018 sobre la carga anticolinérgica presente en las formulaciones antes, durante y después de la atención hospitalaria, evaluando además polifarmacia y prescripciones potencialmente inapropiadas. Se midieron variables sociodemográficas, farmacológicas y de comedicación. Se evaluó la carga anticolinérgica utilizando las escalas ADS, ACB y ARS. Las prescripciones potencialmente inapropiadas se evaluaron mediante los criterios STOPP/START y se definió como polifarmacia 5-9 medicamentos. Se diseñó una base de datos sobre el consumo de fármacos, se utilizó la prueba ji cuadrado para el análisis de las variables categóricas y modelos de regresión logística binaria. El análisis de consistencia se realizó mediante el coeficiente kappa con ponderación cuadrática. Resultados: El estudio incluyó 220 pacientes con fracturas. La edad media fue de 75,3 ± 10,3 años y el 68,2% de pacientes correspondió a mujeres. La fractura más frecuente fue la de cadera (37,7%). La polifarmacia, las prescripciones potencialmente inapropiadas y la carga anticolinérgica fueron mayor durante la hospitalización. La escala ACB identificó la mayor carga anticolinérgica al ingreso hospitalario (35,7%), mientras que la escala ADS identificó más pacientes durante la hospitalización (77,7%) y al egreso (72,1%). La consistencia de las escalas varió en cada uno de los momentos de la prescripción, presentando la mejor correlación al ingreso con las escalas ADS y ACB (71%) mientras que durante la hospitalización y al egreso lo fueron las escalas ACB y ARS (61% y 56%, respectivamente). La prescripción de 5 o más fármacos fue factor de riesgo para recibir medicamentos anticolinérgicos y prescripciones potencialmente inapropiadas. Conclusiones: Las escalas de carga anticolinérgica en este estudio no son intercambiables y los resultados se modifican ostensiblemente en los diferentes momentos en los que se realizan las prescripciones, siendo la escala ADS la herramienta que más identificó medicamentos antimuscarínicos contrastando con la baja proporción de fármacos captada por la escala ARS.eng
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad de Cartagenaspa
dc.rightsDerechos reservados - Universidad de Cartagena, 2018spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.titleConsistencia entre escalas de carga anticolinérgica y prescripciones potencialmente inapropiadas en el adulto mayor con fracturas, en tres centros de referencia, Colombia, 2018spa
dc.typeTrabajo de grado - Maestríaspa
dcterms.referencesRodrigues MCS, Oliveira Cd. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. Rev Latino-Am Enfermagem. 2016;24.spa
dcterms.referencesDepartamento Administrativo Nacional de Estadística de Colombia (DANE). Censo general 2005 [internet]. [Consultado: 25 de Diciembre 2017]. Disponible en: http://www.dane.gov.co/files/censoslibroCenso2005nacional.pdf.spa
dcterms.referencesDepartamento Administrativo Nacional de Estadística de Colombia (DANE). Proyecciones de población [internet]. [Consultado: 25 de Diciembre 2017]. Disponible en: http://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-ypoblacion/proyecciones-de-poblacion.spa
dcterms.referencesPage AT, Potter K, Clifford R, Etherton-Beer C. Deprescribing in older people. Maturitas. 2016;91:115-34.spa
dcterms.referencesDavies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. British journal of clinical pharmacology. 2015;80(4):796-807.spa
dcterms.referencesKim J, Parish AL. Polypharmacy and Medication Management in Older Adults. The Nursing clinics of North America. 2017;52(3):457-68.
dcterms.referencesAlpert PT, Gatlin T. Polypharmacy in Older Adults. Home healthcare now. 2015;33(10):524-9; quiz 30-1.
dcterms.referencesSkinner M. A literature review: polypharmacy protocol for primary care. Geriatric nursing (New York, NY). 2015;36(5):367-71.e4.
dcterms.referencesFick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Archives of internal medicine. 2003;163(22):2716-24.
dcterms.referencesBilyeu KM, Gumm CJ, Fitzgerald JM, Fox SW, Selig PM. Cultivating quality: Reducing the use of potentially inappropriate medications in older adults. The American journal of nursing. 2011;111(1):47-52.
dcterms.referencesGujjarlamudi HB. Polytherapy and drug interactions in elderly. Journal of mid-life health. 2016;7(3):105-7.
dcterms.referencesAlldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. The Cochrane database of systematic reviews. 2016;2:Cd009095.
dcterms.referencesHajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. The American journal of geriatric pharmacotherapy. 2007;5(4):345-51.
dcterms.referencesMachado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME, Chica L. Deprescribing: a new goal focused on the patient. Expert opinion on drug safety. 2017;16(2):111-2.
dcterms.referencesCooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ open. 2015;5(12):e009235.
dcterms.referencesCadogan CA, Ryan C, Hughes CM. Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many. Drug safety. 2016;39(2):109-16.
dcterms.referencesAntimisiaris D, Cutler T. Managing Polypharmacy in the 15-Minute Office Visit. Primary care. 2017;44(3):413-28.
dcterms.referencesLevy HB. Polypharmacy Reduction Strategies: Tips on Incorporating American Geriatrics Society Beers and Screening Tool of Older People's Prescriptions Criteria. Clinics in geriatric medicine. 2017;33(2):177-87.
dcterms.referencesStorms H, Marquet K, Aertgeerts B, Claes N. Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: A systematic review. The European journal of general practice. 2017;23(1):69-77.
dcterms.referencesVerdoorn S, Kwint H-F, Faber A, Gussekloo J, Bouvy ML. Majority of drug-related problems identified during medication review are not associated with STOPP/START criteria. European journal of clinical pharmacology. 2015;71(10):1255-62.
dcterms.referencesBeuscart JB, Dupont C, Defebvre MM, Puisieux F. Potentially inappropriate medications (PIMs) and anticholinergic levels in the elderly: a population based study in a French region. Archives of gerontology and geriatrics. 2014;59(3):630-5.
dcterms.referencesGerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert opinion on drug safety. 2011;10(5):751-65.
dcterms.referencesNishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: theoretical and clinical overview. Expert opinion on drug safety. 2016;15(6):753-68.
dcterms.referencesMachado-Alba JE, Castro-Rodriguez A, Alzate-Piedrahita JA, Hoyos-Pulgarin JA, Medina-Morales DA. Anticholinergic Risk and Frequency of Anticholinergic Drug Prescriptions in a Population Older Than 65. Journal of the American Medical Directors Association. 2016;17(3):275.e1-4.
dcterms.referencesCarnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. Journal of clinical pharmacology. 2006;46(12):1481-6.
dcterms.referencesLee MSS, Hanger HC. Audit of anticholinergic medication changes in older hospitalised patients using the Anticholinergic Drug Scale. Internal medicine journal. 2017;47(6):689-94.
dcterms.referencesSalahudeen MS, Nishtala PS. Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research. Drugs & aging. 2016;33(5):305-13.
dcterms.referencesAmbrose AF, Cruz L, Paul G. Falls and Fractures: A systematic approach to screening and prevention. Maturitas. 2015;82(1):85-93.
dcterms.referencesEnsrud KE. Epidemiology of fracture risk with advancing age. The journals of gerontology Series A, Biological sciences and medical sciences. 2013;68(10):1236-42.
dcterms.referencesBerry SD, Miller R. Falls: Epidemiology, Pathophysiology, and Relationship to Fracture. Current osteoporosis reports. 2008;6(4):149-54.
dcterms.referencesMachado-Duque ME, Castano-Montoya JP, Medina-Morales DA, CastroRodriguez A, Gonzalez-Montoya A, Machado-Alba JE. Drugs With Anticholinergic Potential and Risk of Falls With Hip Fracture in the Elderly Patients: A Case-Control Study. Journal of geriatric psychiatry and neurology. 2018;31(2):63-9.
dcterms.referencesCollamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging clinical and experimental research. 2016;28(1):25- 35.
dcterms.referencesCourt-Brown CM, Clement ND, Duckworth AD, Aitken S, Biant LC, McQueen MM. The spectrum of fractures in the elderly. The bone & joint journal. 2014;96-b(3):366-72.
dcterms.referencesCummings-Vaughn LA, Gammack JK. Falls, osteoporosis, and hip fractures. The Medical clinics of North America. 2011;95(3):495-506, x.
dcterms.referencesRudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of internal medicine. 2008;168(5):508-13.
dcterms.referencesKersten H, Wyller TB. Anticholinergic drug burden in older people's brain - how well is it measured? Basic & clinical pharmacology & toxicology. 2014;114(2):151-9.
dcterms.referencesSalahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC geriatrics. 2015;15:31.
dcterms.referencesDuran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. European journal of clinical pharmacology. 2013;69(7):1485-96
dcterms.referencesMayer T, Meid AD, Saum KU, Brenner H, Schottker B, Seidling HM, et al. Comparison of Nine Instruments to Calculate Anticholinergic Load in a Large Cohort of Older Outpatients: Association with Cognitive and Functional Decline, Falls, and Use of Laxatives. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2017;25(5):531-40.
dcterms.referencesNaples JG, Marcum ZA, Perera S, Gray SL, Newman AB, Simonsick EM, et al. Concordance among anticholinergic burden scales. Journal of the American Geriatrics Society. 2015;63(10):2120-4.
dcterms.referencesTurro-Garriga O, Calvo-Perxas L, Vilalta-Franch J, Blanco-Silvente L, Castells X, Capella D, et al. Measuring anticholinergic exposure in patients with dementia: A comparative study of nine anticholinergic risk scales. Int J Geriatr Psychiatry. 2018.
dcterms.referencesLam MP, Cheung BM. The use of STOPP/START criteria as a screening tool for assessing the appropriateness of medications in the elderly population. Expert review of clinical pharmacology. 2012;5(2):187-97.
dcterms.referencesMera F, Mestre D, Almeda J, Ferrer A, Formiga F, Rojas Farreras S, et al. Paciente anciano y medicación crónica inapropiada en la comunidad ¿somos conscientes de ello? Rev Esp Geriatr Gerontol 2011;46(3):125-30.
dcterms.referencesSumukadas D, McMurdo ME, Mangoni AA, Guthrie B. Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data. Age and ageing. 2014;43(4):515-21.
dcterms.referencesDelgado Silveira E, Montero Errasquín B, Muñoz García M, Vélez-Díaz-Pallarés M, Lozano Montoya I, Sánchez-Castellano C, et al. Mejorando la prescripción de medicamentos en las personas mayores: una nueva edición de los criterios STOPPSTART. Revista Española de Geriatría y Gerontología. 2015;50(2):89-96.
dcterms.referencesGillette C, Prunty L, Wolcott J, Broedel-Zaugg K. A new lexicon for polypharmacy: Implications for research, practice, and education. Research in social & administrative pharmacy : RSAP. 2015;11(3):468-71.
dcterms.referencesWelker KL, Mycyk MB. Pharmacology in the Geriatric Patient. Emergency medicine clinics of North America. 2016;34(3):469-81.
dcterms.referencesGrimmsmann T, Himmel W. Polypharmacy in primary care practices: an analysis using a large health insurance database. Pharmacoepidemiology and drug safety. 2009;18(12):1206-13.
dcterms.referencesMasnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC geriatrics. 2017;17:230.
dcterms.referencesMortazavi SS, Shati M, Keshtkar A, Malakouti SK, Bazargan M, Assari S. Defining polypharmacy in the elderly: a systematic review protocol. BMJ open. 2016;6(3):e010989.
dcterms.referencesHammond T, Wilson A. Polypharmacy and falls in the elderly: a literature review. Nursing and midwifery studies. 2013;2(2):171-5.
dcterms.referencesGomez C, Vega-Quiroga S, Bermejo-Pareja F, Medrano MJ, Louis ED, BenitoLeon J. Polypharmacy in the Elderly: A Marker of Increased Risk of Mortality in a Population-Based Prospective Study (NEDICES). Gerontology. 2015;61(4):301-9.
dcterms.referencesNishtala PS, Narayan SW, Wang T, Hilmer SN. Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiology and drug safety. 2014;23(7):753-8.
dcterms.referencesHovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clinics in geriatric medicine. 2012;28(2):159-72.
dcterms.referencesHitzeman N, Belsky K. Appropriate use of polypharmacy for older patients. American family physician. 2013;87(7):483-4.
dcterms.referencesBudnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. The New England journal of medicine. 2011;365(21):2002-12.
dcterms.referencesStevens CL, Torke AM. Geriatric Trauma: A Clinical and Ethical Review. Journal of trauma nursing : the official journal of the Society of Trauma Nurses. 2016;23(1):36- 41; quiz E3-4.
dcterms.referencesHubbard RE, O'Mahony MS, Woodhouse KW. Medication prescribing in frail older people. European journal of clinical pharmacology. 2013;69(3):319-26.
dcterms.referencesHubbard RE, Peel NM, Scott IA, Martin JH, Smith A, Pillans PI, et al. Polypharmacy among inpatients aged 70 years or older in Australia. The Medical journal of Australia. 2015;202(7):373-7.
dcterms.referencesHolguín-Hernández E, Orozco-Díaz JG. Medicación potencialmente inapropiada en ancianos en un hospital de primer nivel, Bogotá 2007. Rev salud pública. 2010;12(2):287-99.
dcterms.referencesHolguín E, Orozco J. Medicación potencialmente inapropiada en ancianos en un hospital de cuarto nivel en Bogotá. Universitas Médica. 2011;52(2):149-68.
dcterms.referencesCano-Guitierrez C, Samper-Ternent R, Cabrera J, Rosselli D. Uso de medicamentos en adultos mayores de Bogotá, Colombia. Revista Peruana de Medicina Experimental y Salud Publica. 2016;33:419-24.
dcterms.referencesTommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. European journal of clinical pharmacology. 2015;71(12):1415-27.
dcterms.referencesHill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. Journal of clinical pharmacy and therapeutics. 2016;41(2):158-69.
dcterms.referencesDesnoyer A, Guignard B, Lang PO, Desmeules J, Vogt-Ferrier N, Bonnabry P. [Potentially inappropriate medications in geriatrics: Which tools to detect them?]. Presse medicale (Paris, France : 1983). 2016;45(11):957-70.
dcterms.referencesFuentes P, Webar J. Prescripción de fármacos en el adulto mayor. Medwave. 2013;13(04):e5662-e.
dcterms.referencesHill-Taylor B, Sketris I, Hayden J, Byrne S, O'Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. Journal of clinical pharmacy and therapeutics. 2013;38(5):360-72.
dcterms.referencesHansen CR, Byrne S, Cullinan S, O'Mahony D, Sahm LJ, Kearney PM. Longitudinal patterns of potentially inappropriate prescribing in early old-aged people. European journal of clinical pharmacology. 2017.
dcterms.referencesPretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. American family physician. 2013;87(5):331-6.
dcterms.referencesAmerican Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2015;63(11):2227-46.
dcterms.referencesHamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Archives of internal medicine. 2011;171(11):1013-9.
dcterms.referencesPastor Cano J, Aranda Garcia A, Gascon Canovas JJ, Rausell Rausell VJ, Tobaruela Soto M. [Spanish adaptation of Beers criteria]. Anales del sistema sanitario de Navarra. 2015;38(3):375-85.
dcterms.referencesGallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. International journal of clinical pharmacology and therapeutics. 2008;46(2):72-83.
dcterms.referencesCastro-Rodriguez AJ, Orozco-Hernandez JP, Marin-Medina DS. Polifarmacia y prescripción de medicamentos potencialmente no apropiados en ancianos. Rev Med Risaralda. 2015;21(2):52-7.
dcterms.referencesO'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and ageing. 2015;44(2):213-8.
dcterms.referencesBarenholtz Levy H, Marcus EL. Potentially Inappropriate Medications in Older Adults: Why the Revised Criteria Matter. The Annals of pharmacotherapy. 2016;50(7):599-603.
dcterms.referencesvan der Stelt CA, Vermeulen Windsant-van den Tweel AM, Egberts AC, van den Bemt PM, Leendertse AJ, Hermens WA, et al. The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study. Drug safety. 2016;39(1):79-87.
dcterms.referencesMimica Matanovic S, Vlahovic-Palcevski V. Potentially inappropriate medications in the elderly: a comprehensive protocol. European journal of clinical pharmacology. 2012;68(8):1123-38.
dcterms.referencesPatton DE, Hughes CM, Cadogan CA, Ryan CA. Theory-Based Interventions to Improve Medication Adherence in Older Adults Prescribed Polypharmacy: A Systematic Review. Drugs & aging. 2017;34(2):97-113.
dcterms.referencesSoukup O, Winder M, Killi UK, Wsol V, Jun D, Kuca K, et al. Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. Current Neuropharmacology. 2017;15(4):637-53.
dcterms.referencesWess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature reviews Drug discovery. 2007;6(9):721-33.
dcterms.referencesCaulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacological reviews. 1998;50(2):279-90.
dcterms.referencesLeach K, Simms J, Sexton PM, Christopoulos A. Structure-function studies of muscarinic acetylcholine receptors. Handbook of experimental pharmacology. 2012(208):29-48.
dcterms.referencesLampela P, Paajanen T, Hartikainen S, Huupponen R. Central Anticholinergic Adverse Effects and Their Measurement. Drugs & aging. 2015;32(12):963-74.
dcterms.referencesFerreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer's Disease: Targeting the Cholinergic System. Current Neuropharmacology. 2016;14(1):101-15.
dcterms.referencesForeman JC, Johansen T, Gibb AJ. Textbook of Receptor Pharmacology, Third Edition: Taylor & Francis; 2011.
dcterms.referencesEglen RM. Overview of muscarinic receptor subtypes. Handbook of experimental pharmacology. 2012(208):3-28.
dcterms.referencesHaga T. Molecular properties of muscarinic acetylcholine receptors. Proceedings of the Japan Academy Series B, Physical and biological sciences. 2013;89(6):226-56.
dcterms.referencesNathanson NM. Synthesis, trafficking, and localization of muscarinic acetylcholine receptors. Pharmacology & therapeutics. 2008;119(1):33-43.
dcterms.referencesElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. American journal of therapeutics. 2007;14(5):488-98.
dcterms.referencesBritt DM, Day GS. Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. Missouri medicine. 2016;113(3):207-14.
dcterms.referencesKachru N, Carnahan RM, Johnson ML, Aparasu RR. Potentially inappropriate anticholinergic medication use in community-dwelling older adults: a national crosssectional study. Drugs & aging. 2015;32(5):379-89.
dcterms.referencesPatterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy for older people. The Cochrane database of systematic reviews. 2014(10):Cd008165.
dcterms.referencesRuxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. British journal of clinical pharmacology. 2015;80(2):209-20.
dcterms.referencesCardwell K, Hughes CM, Ryan C. The Association Between Anticholinergic Medication Burden and Health Related Outcomes in the 'Oldest Old': A Systematic Review of the Literature. Drugs & aging. 2015;32(10):835-48.
dcterms.referencesRichardson K, Bennett K, Maidment ID, Fox C, Smithard D, Kenny RA. Use of Medications with Anticholinergic Activity and Self-Reported Injurious Falls in Older Community-Dwelling Adults. Journal of the American Geriatrics Society. 2015;63(8):1561-9.
dcterms.referencesVillalba-Moreno AM, Alfaro-Lara ER, Perez-Guerrero MC, Nieto-Martin MD, Santos-Ramos B. Systematic review on the use of anticholinergic scales in poly pathological patients. Archives of gerontology and geriatrics. 2016;62:1-8.
dcterms.referencesLopez-Alvarez J, Zea-Sevilla MA, Aguera Ortiz L, Fernandez Blazquez MA, Soler MV, Martinez-Martin P. Efecto de los fármacos anticolinérgicos en el rendimiento cognitivo de las personas mayores. Revista de Psiquiatría y Salud Mental. 215;8:35-43.
dcterms.referencesReeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert opinion on drug metabolism & toxicology. 2015;11(4):491-508.
dcterms.referencesBowie MW, Slattum PW. Pharmacodynamics in older adults: a review. The American journal of geriatric pharmacotherapy. 2007;5(3):263-303.
dcterms.referencesCancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurological sciences :official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2009;30(2):87-92.
dcterms.referencesTune LE, Egeli S. Acetylcholine and Delirium. Dementia and Geriatric Cognitive Disorders. 1999;10(5):342-4.
dcterms.referencesLertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expertbased drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2013;13(1):17-24.
dcterms.referencesTune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Archives of general psychiatry. 1980;37(3):293-7.
dcterms.referencesChew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatrics Society. 2008;56(7):1333-41.
dcterms.referencesSalahudeen MS, Chyou T-y, Nishtala PS. Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature. PloS one. 2016;11(3):e0151084.
dcterms.referencesPlaschke K, Thomas C, Engelhardt R, Teschendorf P, Hestermann U, Weigand MA, et al. Significant correlation between plasma and CSF anticholinergic activity in presurgical patients. Neuroscience letters. 2007;417(1):16-20.
dcterms.referencesRudd K, L Raehl C, A Bond C, J Abbruscato T, C Stenhouse A. Methods for Assessing Drug-Related Anticholinergic Activity2005. 1592-601 p.
dcterms.referencesBostock CV, Soiza RL, Mangoni AA. Association between prescribing of antimuscarinic drugs and antimuscarinic adverse effects in older people. Expert review of clinical pharmacology. 2010;3(4):441-52.
dcterms.referencesMangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2013;21(8):785-93.
dcterms.referencesCarnahan RM, Lund BC, Perry PJ, Pollock BG. A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacology bulletin. 2002;36(2):24-39.
dcterms.referencesCox EA, Kwatra SG, Shetty S, Kwatra MM. Flaws in the serum anticholinergic activity assay: implications for the study of delirium. Journal of the American Geriatrics Society. 2009;57(9):1707-8.
dcterms.referencesNishtala PS, Fois RA, McLachlan AJ, Bell JS, Kelly PJ, Chen TF. Anticholinergicactivity of commonly prescribed medications and neuropsychiatric adverse events in older people. Journal of clinical pharmacology. 2009;49(10):1176-84.
dcterms.referencesSalahudeen MS, Duffull SB, Nishtala PS. Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review. Drugs & aging. 2014;31(3):185-92.
dcterms.referencesWawruch M, Macugova A, Kostkova L, Luha J, Dukat A, Murin J, et al. The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients. Pharmacoepidemiology and drug safety. 2012;21(2):170-6.
dcterms.referencesHan L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Archives of internal medicine. 2001;161(8):1099-105.
dcterms.referencesBoustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-20.
dcterms.referencesHilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Archives of internal medicine. 2007;167(8):781-7.
dcterms.referencesWoolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Metaanalysis of the impact of 9 medication classes on falls in elderly persons. Archives of internal medicine. 2009;169(21):1952-60.
dcterms.referencesMachado-Duque ME, Castano-Montoya JP, Medina-Morales DA, CastroRodriguez A, Gonzalez-Montoya A, Machado-Alba JE. Association between the use of benzodiazepines and opioids with the risk of falls and hip fractures in older adults. International psychogeriatrics. 2017:1-6.
dcterms.referencesHsu WH, Wen YW, Chen LK, Hsiao FY. Comparative Associations Between Measures of Anti-cholinergic Burden and Adverse Clinical Outcomes. Annals of family medicine. 2017;15(6):561-9.
dcterms.referencesHochberg MC. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. Current osteoporosis reports. 2008;6(3):89-94.
dcterms.referencesGerdhem P. Osteoporosis and fragility fractures: Vertebral fractures. Best practice research Clinical rheumatology. 2013;27(6):743-55.
dcterms.referencesDel Pino-Montes J. Epidemiology of osteoporotic fractures: vertebral and nonvertebral fractures. Rev Osteoporos Metab Miner. 2010;2(5):8-12.
dcterms.referencesBurge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2007;22(3):465-75.
dcterms.referencesSchousboe JT. Epidemiology of Vertebral Fractures. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2016;19(1):8-22.
dcterms.referencesPapaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko N. Diagnosis and management of vertebral fractures in elderly adults. The American journal of medicine. 2002;113(3):220-8.
dcterms.referencesAigner R, Meier Fedeler T, Eschbach D, Hack J, Bliemel C, Ruchholtz S, et al. Patient factors associated with increased acute care costs of hip fractures: a detailed analysis of 402 patients. Archives of osteoporosis. 2016;11(1):38.
dcterms.referencesMaghbooli Z, Hossein-Nezhad A, Jafarpour M, Noursaadat S, Ramezani M, Hashemian R, et al. Direct costs of osteoporosis-related hip fractures: protocol for a cross-sectional analysis of a national database. BMJ open. 2017;7(4):e014898.
dcterms.referencesPike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. PharmacoEconomics. 2010;28(5):395-409.
dcterms.referencesHarstedt M, Rogmark C, Sutton R, Melander O, Fedorowski A. Polypharmacy and adverse outcomes after hip fracture surgery. Journal of orthopaedic surgery and research. 2016;11(1):151.
dcterms.referencesSahota O, Morgan N, Moran CG. The direct cost of acute hip fracture care in care home residents in the UK. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012;23(3):917-20.
dcterms.referencesBudhia S, Mikyas Y, Tang M, Badamgarav E. Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. PharmacoEconomics. 2012;30(2):147-70.
dcterms.referencesPike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET. Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2- year period in the US. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2011;22(1):47-56.
dcterms.referencesSi L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ. Projection of osteoporosisrelated fractures and costs in China: 2010-2050. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2015;26(7):1929-37.
dcterms.referencesPont LG, Nielen JT, McLachlan AJ, Gnjidic D, Chan L, Cumming RG, et al. Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures. British journal of clinical pharmacology. 2015;80(5):1169-75.
dcterms.referencesDuffau T. G. Tamaño muestral en estudios biomédicos. Revista chilena de pediatría. 1999;70:314-24
dcterms.referencesHanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29-36.
dcterms.referencesLu W-H, Wen Y-W, Chen L-K, Hsiao F-Y. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ : Canadian Medical Association Journal. 2015;187(4):E130-E7
dcterms.referencesGonzáles I, Becerra M, Gónzales J, Campos A, Barbosa J, Alvarado J. Fracturas de cadera: satisfacción posquirúrgica al año en adultos mayores atendidos en MéderiHospital Universitario Mayor, Bogotá, D.C. Rev Cienc Salud. 2015;14(3):409-22.
dcterms.referencesCourt-Brown CM, McQueen MM. Global Forum: Fractures in the Elderly. JBJS. 2016;98(9):e36.
dcterms.referencesPatel D, Ackermann RJ. Issues in Geriatric Care: Falls. FP essentials. 2018;468:18-25.
dcterms.referencesBischoff-Ferrari HA. The role of falls in fracture prediction. Current osteoporosis reports. 2011;9(3):116-21.
dcterms.referencesTran T, Bliuc D, van Geel T, Adachi JD, Berger C, van den Bergh J, et al. Population-Wide Impact of Non-Hip Non-Vertebral Fractures on Mortality. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017;32(9):1802-10.
dcterms.referencesSanchez-Riera L, Wilson N. Fragility Fractures & Their Impact on Older People. Best practice & research Clinical rheumatology. 2017;31(2):169-91.
dcterms.referencesZia A, Kamaruzzaman SB, Tan MP. The consumption of two or more fall riskincreasing drugs rather than polypharmacy is associated with falls. Geriatrics & gerontology international. 2017;17(3):463-70.
dcterms.referencesPan H-H, Li C-Y, Chen T-J, Su T-P, Wang K-Y. Association of polypharmacy with fall-related fractures in older Taiwanese people: age- and gender-specific analyses. BMJ open. 2014;4(3).
dcterms.referencesAguilar del Rey FJ, Pérez González O. Epidemiología de las fracturas osteoporóticas en Andalucía en el período 2000-2010. Medicina Clínica. 2018;150(8):297-302.
dcterms.referencesDel Duca GF, Antes DL, Hallal PC. Quedas e fraturas entre residentes de instituições de longa permanência para idosos. Revista Brasileira de Epidemiologia. 2013;16:68-76.
dcterms.referencesRoux S, Cabana F, Carrier N, Beaulieu M, April PM, Beaulieu MC, et al. The World Health Organization Fracture Risk Assessment Tool (FRAX) underestimates incident and recurrent fractures in consecutive patients with fragility fractures. The Journal of clinical endocrinology and metabolism. 2014;99(7):2400-8.
dcterms.referencesCurtis EM, van der Velde R, Moon RJ, van den Bergh JP, Geusens P, de Vries F, et al. Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status. Bone. 2016;87:19-26.
dcterms.referencesLiu SK, Munson JC, Bell J-E, Zaha RL, Mecchella JN, Tosteson ANA, et al. Quality of Osteoporosis Care Among Older Medicare Fragility Fracture Patients 2006– 2010. Journal of the American Geriatrics Society. 2013;61(11):1855-62.
dcterms.referencesFormiga F, Navarro M, Duaso E, Chivite D, Ruiz D, Perez-Castejon JM, et al. Factors associated with hip fracture-related falls among patients with a history of recurrent falling. Bone. 2008;43(5):941-4.
dcterms.referencesRichardson K, Bennett K, Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age and ageing. 2015;44(1):90-6.
dcterms.referencesMinisterio de Salud y Protección Social. Cifras del aseguramiento en salud [internet]. [Consultado: 9 de Julio 2018]. Disponible en: https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx.
dcterms.referencesHernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Archives of osteoporosis. 2013;8(1-2):136.
dcterms.referencesHaentjens P, Autier P, Collins J, Velkeniers B, Vanderschueren D, Boonen S. Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis. The Journal of bone and joint surgery American volume. 2003;85- a(10):1936-43.
dcterms.referencesFriedman SM, Mendelson DA. Epidemiology of fragility fractures. Clinics in geriatric medicine. 2014;30(2):175-81.
dcterms.referencesHuang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs & aging. 2012;29(5):359-76.
dcterms.referencesUribe-Ríos A, Castaño-Herrera DA, García-Ortega AN, Pardo-Aluma EE. Morbilidad y mortalidad en pacientes mayores de 60 años con fractura de cadera en el Hospital Universitario San Vicente Fundación, de Medellín, Colombia. Iatreia. 2012;25(4):305-13.
dcterms.referencesMartinez-Rondanelli A. Fractura de cadera en acianos. Pronóstico, epidemiología, aspectos generales, experiencia. Rev Col de Or Tra. 2005;19(1).
dcterms.referencesClark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2009;20(2):275-82.
dcterms.referencesCalle-Toro JS, Sanchez AI, Morales M, García AF. Trauma en ancianos - Experiencia de dos hospitales de referencia en Cali, Colombia. Panam J Trauma Crit Care Emerg Surg. 2016;5(1):38-42.
dcterms.referencesWorld Health Organization. WHO Global Report on Falls Prevention in Older Age 2007 [internet]. [Consultado: 10 de Julio 2018]. Disponible en: http://www.who.int/ageing/publications/Falls_prevention7March.pdf.
dcterms.referencesRubenstein LZ. Falls in older people: epidemiology, risk factors and strategies for prevention. Age and ageing. 2006;35 Suppl 2:ii37-ii41.
dcterms.referencesKwan MM, Close JC, Wong AK, Lord SR. Falls incidence, risk factors, and consequences in Chinese older people: a systematic review. Journal of the American Geriatrics Society. 2011;59(3):536-43.
dcterms.referencesRubenstein LZ, Josephson KR. Falls and their prevention in elderly people: what does the evidence show? The Medical clinics of North America. 2006;90(5):807-24.
dcterms.referencesTinetti ME, Kumar C. The patient who falls: "It's always a trade-off". Jama. 2010;303(3):258-66.
dcterms.referencesCampbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. Journal of the American Geriatrics Society. 1999;47(7):850-3.
dcterms.referencesCampbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. Journal of the American Geriatrics Society. 1999;47(7):850-3.
dcterms.referencesKomagamine J, Hagane K. Intervention to improve the appropriate use of polypharmacy for older patients with hip fractures: an observational study. BMC geriatrics. 2017;17:288.
dcterms.referencesSattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nature reviews Endocrinology. 2014;10(10):592-602.
dcterms.referencesAbrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2009;20(10):1633- 50.
dcterms.referencesCourt-Brown CM, McQueen MM. Global Forum: Fractures in the Elderly. The Journal of bone and joint surgery American volume. 2016;98(9):e36.
dcterms.referencesNeila Calvo S, Nan Nan D, García Ibarbia C, Olmos Martínez JM, González Macías J, Hernández Hernández JL. La realidad de la osteoporosis en el paciente hospitalizado en Medicina Interna. Revista de Osteoporosis y Metabolismo Mineral. 2013;5:141-5.
dcterms.referencesKim SC, Kim MS, Sanfelix-Gimeno G, Song HJ, Liu J, Hurtado I, et al. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. The American journal of medicine. 2015;128(5):519-26.e1.
dcterms.referencesCuevas-Trisan R. Balance Problems and Fall Risks in the Elderly. Physical medicine and rehabilitation clinics of North America. 2017;28(4):727-37.
dcterms.referencesMenzies IB, Mendelson DA, Kates SL, Friedman SM. The Impact of Comorbidity on Perioperative Outcomes of Hip Fractures in a Geriatric Fracture Model. Geriatric Orthopaedic Surgery & Rehabilitation. 2012;3(3):129-34.
dcterms.referencesDominguez LJ, Scalisi R, Barbagallo M. Therapeutic options in osteoporosis. Acta bio-medica : Atenei Parmensis. 2010;81 Suppl 1:55-65.
dcterms.referencesMilat F, Ebeling PR. Osteoporosis treatment: a missed opportunity. The Medical journal of Australia. 2016;205(4):185-90.
dcterms.referencesGarcía J, Guerrero EA, Terront A, Molina JF, Pérez C, Jannaut MJ, et al. Costos de fracturas en mujeres con osteoporosis en Colombia. Acta Med Colom. 2014;39:46- 56.
dcterms.referencesZiere G, Dieleman JP, Hofman A, Pols HA, van der Cammen TJ, Stricker BH. Polypharmacy and falls in the middle age and elderly population. British journal of clinical pharmacology. 2006;61(2):218-23.
dcterms.referencesIolascon G, Cisari C, Moretti A, Frizzi L, Gimigliano R, Gimigliano F. NSAIDs and opioids in management of fragility fractures. Aging clinical and experimental research. 2013;25 Suppl 1:S97-100.
dcterms.referencesAnnika K, Sölve E, Isam A. Older Adults' Medication Use 6 Months Before and After Hip Fracture: A Population‐ Based Cohort Study. Journal of the American Geriatrics Society. 2011;59(5):863-8.
dcterms.referencesKarani R, Meier DE. Systemic pharmacologic postoperative pain management in the geriatric orthopaedic patient. Clinical orthopaedics and related research. 2004(425):26-34.
dcterms.referencesMalec M, Shega JW. Pain management in the elderly. The Medical clinics of North America. 2015;99(2):337-50.
dcterms.referencesMejjad O, Serrie A, Ganry H. Epidemiological data, efficacy and safety of a paracetamol-tramadol fixed combination in the treatment of moderate-to-severe pain. SALZA: a post-marketing study in general practice. Current medical research and opinion. 2011;27(5):1013-20.
dcterms.referencesDhillon S. Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain. Clinical drug investigation. 2010;30(10):711-38.
dcterms.referencesVandenbroucke A, Luyten FP, Flamaing J, Gielen E. Pharmacological treatment of osteoporosis in the oldest old. Clinical Interventions in Aging. 2017;12:1065-77.
dcterms.referencesWilkins CH, Birge SJ. Prevention of osteoporotic fractures in the elderly. The American journal of medicine. 2005;118(11):1190-5.
dcterms.referencesCerocchi I, Ghera S, Gasbarra E, Scialdoni A, Tarantino U. Fragility fractures: the clinical pathway. Aging clinical and experimental research. 2013;25 Suppl 1:S43-5.
dcterms.referencesTang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet (London, England). 2007;370(9588):657-66.
dcterms.referencesBoonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. The Journal of clinical endocrinology and metabolism. 2007;92(4):1415-23.
dcterms.referencesFlais J, Coiffier G, Le Noach J, Albert JD, Faccin M, Perdriger A, et al. Low prevalence of osteoporosis treatment in patients with recurrent major osteoporotic fracture. Archives of osteoporosis. 2017;12(1):24.
dcterms.referencesLiu Z, Weaver J, de Papp A, Li Z, Martin J, Allen K, et al. Disparities in osteoporosis treatments. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016;27(2):509-19.
dcterms.referencesZia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: Balancing evidence-based medicine against falls risk. Postgraduate medicine. 2015;127(3):330-7.
dcterms.referencesPark H, Satoh H, Miki A, Urushihara H, Sawada Y. Medications associated with falls in older people: systematic review of publications from a recent 5-year period. European journal of clinical pharmacology. 2015;71(12):1429-40.
dcterms.referencesBurkhardt H, Wehling M, Gladisch R. [Prevention of adverse drug reactions in older patients]. Zeitschrift fur Gerontologie und Geriatrie. 2007;40(4):241-54.
dcterms.referencesOlmos R, Garcia O, Velasco J, de la Rubia A. Prevalence of polypharmacy in older hospitalised patients. European Journal of Hospital Pharmacy: Science and Practice. 2012;19(2):242-3.
dcterms.referencesWawruch M, Zikavska M, Wsolova L, Kuzelova M, Tisonova J, Gajdosik J, et al. Polypharmacy in elderly hospitalised patients in Slovakia. Pharmacy world & science : PWS. 2008;30(3):235-42.
dcterms.referencesHartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. The journals of gerontology Series A, Biological sciences and medical sciences. 2007;62(10):1172-81.
dcterms.referencesLonnbro J, Wallerstedt SM. Clinical relevance of the STOPP/START criteria in hip fracture patients. European journal of clinical pharmacology. 2017;73(4):499-505.
dcterms.referencesBelfrage B, Koldestam A, Sjöberg C, Wallerstedt SM. Number of drugs in the medication list as an indicator of prescribing quality: a validation study of polypharmacy indicators in older hip fracture patients. European journal of clinical pharmacology. 2015;71(3):363-8.
dcterms.referencesGosch M, Wörtz M, Nicholas JA, Doshi HK, Kammerlander C, Lechleitner M. Inappropriate Prescribing as a Predictor for Long-Term Mortality after Hip Fracture.Gosch M, Wörtz M, Nicholas JA, Doshi HK, Kammerlander C, Lechleitner M.Inappropriate Prescribing as a Predictor for Long-Term Mortality after Hip Fracture. Gerontology. 2014;60(2):114-22
dcterms.referencesWahab MS, Nyfort-Hansen K, Kowalski SR. Inappropriate prescribing in hospitalised Australian elderly as determined by the STOPP criteria. International journal of clinical pharmacy. 2012;34(6):855-62.
dcterms.referencesInstituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). Consultas registros sanitarios [internet]. [Consultado: 10 de Julio 2018]. Disponible en: https://www.invima.gov.co/consultas-registros-sanitarios.
dcterms.referencesPergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain practice : the official journal of World Institute of Pain. 2008;8(4):287-313.
dcterms.referencesOriol T-G, Laia C-P, Joan V-F, Lidia B-S, Xavier C, Dolors C, et al. Measuring anticholinergic exposure in patients with dementia: A comparative study of nine anticholinergic risk scales. International Journal of Geriatric Psychiatry. 2018;33(5):710- 7.
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.description.degreelevelMaestríaspa
dc.description.degreenameAbogado(a)spa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeCartagena de Indiasspa
dc.publisher.programMaestría en Farmacologíaspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.subject.armarcFracturas
dc.subject.armarcHuesos - Enfermedades
dc.subject.armarcMedicina del dolor
dc.subject.armarcAnalgesia
dc.subject.armarcDolor - Análisis
dc.subject.armarcMedicamentos
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttps://purl.org/redcol/resource_type/TMspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Derechos reservados - Universidad de Cartagena, 2018
Excepto si se señala otra cosa, la licencia del ítem se describe como Derechos reservados - Universidad de Cartagena, 2018